About PAMPRx

PAMPRx is building a first-in-class, pathogen-agnostic immunotherapy platform that targets the root cause of inflammation: pathogen-associated molecular patterns (PAMPs).

PAMPs—including peptidoglycan (PGN), lipoteichoic acid (LTA), and lipopolysaccharide (LPS)—are conserved structural components of bacterial cell walls. They are continuously shed into the body during infection, microbiome turnover, and antibiotic treatment, where they activate innate immune receptors such as Toll-like receptors (TLRs) and NOD-like receptors (NODs). 

While essential for host defense, persistent exposure to these molecules drives chronic, non-resolving inflammation across a wide range of diseases—from sepsis and metabolic dysfunction to autoimmune and neuroinflammatory conditions. 

Despite their central role in disease biology, no approved therapies directly neutralize these upstream triggers. Instead, today’s $80B+ immunology market is dominated by drugs that block downstream cytokines—treating symptoms rather than eliminating the source of immune activation. 

PAMPRx is redefining this paradigm.

Our platform uses extended half-life, Fc-engineered monoclonal antibodies to neutralize PAMPs before they activate the immune system. By targeting PGN, LTA, and LPS simultaneously, PAMPRx delivers a novel, upstream approach that both:

• Prevents inflammatory signaling at its source, and
• Enhances immune-mediated clearance of bacteria through opsonization and complement activation

This dual mechanism—neutralization plus immune recruitment—creates the first therapy capable of addressing both the inflammatory and microbial components of disease in a single platform. 

Importantly, PAMPRx modulates immune activation without suppressing immune function. Unlike steroids, JAK inhibitors, or cytokine blockers, our approach preserves host defense while eliminating the signals that drive chronic inflammation.

The platform is designed as a specialty biologics franchise, not an antibiotic—with applications spanning acute indications like sepsis and large chronic markets including metabolic disease (MASLD/MASH), autoimmune disorders, and neuroinflammatory conditions. This breadth is enabled by a unifying biological insight: microbial PAMPs are a common upstream driver across seemingly unrelated diseases. 

PAMPRx’s lead program, derived from the LHNVD-501 platform, targets conserved peptidoglycan structures present across Gram-positive, Gram-negative, and mycobacterial organisms—enabling truly pathogen-agnostic activity. The broader pipeline expands this approach into a multi-antibody cocktail designed to comprehensively neutralize the dominant drivers of innate immune activation.

With biomarker-driven clinical development and a clear path across multiple high-value indications, PAMPRx is positioned to establish a new category of medicine: upstream, host-directed immunotherapy for inflammation-driven disease.